Aging is the single most important risk factor for Alzheimer's disease (AD), which represents the most common cause of dementia in the world. Our group has shown that a naturally occurring switch from the TrkA to the p75 neurotrophin receptor system is responsible for the activation of amyloid p-peptide (A[3) that characterizes aging. Such an event occurs downstream of the aging program mediated by the insulin-like growth factor 1 receptor (IGF1-R), and leads to activation of neutral sphingomyelinase (nSMase), the enzyme that generates the lipid second messenger ceramide. Ceramide, in turn, is responsible for the molecular stabilization of BACE1 and the increased production of Ap. The above events can be blocked by genetic and biochemical approaches that target IGF1-R, p75NTR, or nSMase. In the Preliminary Studies Section, we report that ceramide regulates a transient form of lysine acetylation of nascent BACE1 that affects the molecular stability of the p secretase. This process involves lysine acetylation in the lumen of the ER/ERGIC and is followed by deacetylation in the lumen of the Golgi apparatus, once the nascent protein is fully mature. Given the role that BACE1 plays in the molecular pathogenesis of AD, our results have profound implications for the neurobiology of the disease. The central hypothesis of this proposal is that ceramide is the last output of a signaling pathway that controls AD-neuropatholoqy during aging. Specifically, we propose that ceramide regulates AB generation by affecting the acetylation and molecular stability of BACE1, the rate-limiting enzyme for the biogenesis of Ap.
Specific Aim 1 will study the biochemical properties of the acetyl-CoA membrane transporter, which translocates acetylCoA from the cytosol to the lumen of the ER, where it serves as donor of acetyl groups for the molecular stabilization of BACE1.
Specific Aim 2 will study the function and biochemical properties of two newly-identified acetylCoA:lysine acetyltransferases that are required for the molecular stabilization of BACE1, downstream of ceramide. For the execution of the above two Specific Aims, we have described a combination of biochemical and genetic approaches. The biochemical approaches include enzymatic assays, in vitro reconstitution, affinity purification, subcellular fractionation studies, and depletion studies. The genetic approaches include stable transfection and """"""""gene-silencing"""""""" of the above targets. Finally, translational research is described as part of our proposal to translate our findings into novel therapeutic approaches to prevent late-onset AD.

Public Health Relevance

Aging is the single most important risk factor for Alzheimer's disease (AD). Because of the increase in life expectancy that we are experiencing, AD is predicted to affect 45 million individuals worldwide by the year 2050. We have identified a novel molecular pathway that links aging to AD neuropathology. The long-term objective of this proposal is to characterize this pathway and design new approaches for the prevention of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG033514-02
Application #
8051849
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
2
Fiscal Year
2010
Total Cost
$139,399
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Holden, Timothy R; Keller, Sarah; Kim, Alice et al. (2018) Procedural Framework to Facilitate Hospital-Based Informed Consent for Dementia Research. J Am Geriatr Soc 66:2243-2248
Betthauser, Tobey J; Cody, Karly A; Zammit, Matthew D et al. (2018) In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer's disease dementia to young controls. J Nucl Med :
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Hao, Ling; Wang, Jingxin; Page, David et al. (2018) Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer's Disease. Sci Rep 8:9291
Bettcher, Brianne M; Johnson, Sterling C; Fitch, Ryan et al. (2018) Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis 62:385-397
Mueller, Kimberly D; Koscik, Rebecca L; Clark, Lindsay R et al. (2018) The Latent Structure and Test-Retest Stability of Connected Language Measures in the Wisconsin Registry for Alzheimer's Prevention (WRAP). Arch Clin Neuropsychol 33:993-1005
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Zhou, Hao Henry; Singh, Vikas; Johnson, Sterling C et al. (2018) Statistical tests and identifiability conditions for pooling and analyzing multisite datasets. Proc Natl Acad Sci U S A 115:1481-1486

Showing the most recent 10 out of 374 publications